The effect of gabapentin on withdrawal syndrome, psychiatric disorders and electroencephalogram of opium addicts during the detoxification period

Iranian Journal of Pharmaceutical Research

Volumn 3, Issue 4, 2004, Pages 215-223

  Mobasher, Mina ^a   Ziaaddini, Hassan ^b   Moghaddam, Akbar Hamzeii ^b   Sabzvari, Fatima ^b   Sadeghipour, Saleh ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Detoxification period; Electroencephalogram; Gabapentin; Opium; Symptom check list 90 revised

Indexed keywords

EID: 84883758925     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: 10.22037/IJPR.2010.604     Document Type: Article

References (29)

1. Quresh NA, Al-Ghamdy YS and Al-Habeeb TA. Drug addiction: A general review of new concepts and future challenges. East. Med. Health J. (2000) 6: 1-5
2. Helze JE and Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact in treatment. J. Stud. Alcohol (1988) 49: 219-224
3. Kessler RC, McGonagle KA and Zhao SL. Life time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51: 8-19
4. Rounsaville B, Weissman M and Kleber H. Heterogenity of psychiatric diagnosis in treated opiates addicts. Arch. Gen. Psychiatry (1982) 39: 161-166
5. Jaffe JH. Opiates disorders. In: Sadock BJ and Sadock VA (Eds.) A Comperehensive Textbook of Psychiatry. 7th ed. Williams & Wilkins, Philadelphia (2000) 940-949
6. rd ed. Williams & Wilkins (1997) 148-166
7. th ed. Philadelphia (2003) 448-456
8. Logar C, Grabmair W, Reinbacher N and Ladurner G. EEG changes in the withdrawal phase of tranquilizer of drug abuse. Electromyogr. Vermanolite. Geb. (1989) 17: 37-40.
9. Roemor RA, Gornwell A, Dewart D, Jackso P and Ercegovas DR. Quantitative electroencephalographic analyses in cocaine prefering polysubstance abusers during abstinence. Psychiatry Res. (1995) 58: 247-57
10. Goa KL and Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs (1993) 46: 409-27
11. Chadwick D. Gabapentin-drug profile. Lancet (1994) 343:89-91
12. Watson WP, Robinson E and Little HJ. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndroms. Neuropharmacology (1997) 36:1369-75
13. Bonnet U, Bonger M, Leweke FM, Maschke M, Kowalski T and Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry (1999) 32: 107-9
14. Mattson RH. Managing epilepsy: role of gabapentin. Neurology (1994) 44: 3-32
15. Magnue L. Nonepileptic uses of gabapentin. Epilepsia (1999) 40: 66-74
16. Shimoyama M, shimoyama N, Inturris CE and Elliott KJ. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain (1997) 72: 375-82
17. Letterman L and Markowitz JS. Gabapentin: A review of published Experience the treatment of bipolar disorder and other psychiatry conditions. Pharmacotherapy (1999) 19: 656-72
18. Vieta E, Martine-Aran A, Nieto E, Colom F, Reinars M, Benabarre A and Gasto C. Adjunctive gabapentin treatment of bipolar disorder. Eur. Psychiatry (2000) 15: 433-7
19. Kumar P and Jain MK. Gabapentin in the management of pentazocine dependence: a potent analgesic-anticraving agent. Assoc. Physicians India (2003) 51: 673-6
20. Gustorff B, Kozek-Langenecker S and Kress HG. Gabapentin: the first preemptive anti-hyperalgesic for opioid withdrawal hyperalgesia? Anesthesiology (2003) 98: 1520-1
21. nd ed. Blackwell Science, London (1995) 399-401
22. Foulks E and McLellen T. Psychologic sequnel of chronic toxic waste exposure. South. Med. J. (1992) 85: 122-126
23. Hernandez J and Kellner R. Hypochondrical concerns and attitudes toward illness in males and females. Int. J. Psychiatry Med. (1992) 22: 254-263
24. Von Limbeek JV, Wouters L, Kaplan CD, Geerling PJ and Alen W. Prevalence of psychopathology in drug addicted. J. Subs. Abuse Treat. (1992) 9: 43-52
25. Andrews N, Loomis S, Blake R, Ferrigan L, Singh LT and McKnigh A. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (2001) 157: 381-387
26. Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M and Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Neuro-Psychopharmacol. Biol. Psychiatry (2004)28: 599-601
27. Ketter TA, Post RM and Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology (1999) 53: 553-67
28. Cabras PL, Hardoy MJ, Hardoy MC and Carta MG. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder. J. Clin. Psychiatry (1999) 60: 245-8
29. Mattia D, Spanedda F, Bassetti MA, Romigi A, Placidi F and Marciani MG. Gabapentin as add-on therapy in focal epilepsy: A computerized EEG study. Clin. Neurophysiol. (2000) 111: 2311-7